

**COMMONWEALTH OF KENTUCKY**  
**CABINET FOR HEALTH AND FAMILY SERVICES**  
**DEPARTMENT FOR MEDICAID SERVICES**  
**PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**  
**Capitol Annex -Room 131**

700 Capital Avenue Frankfort, Kentucky 40601

Thursday, September 18, 2014  
1:00 P.M. to 4:30 P.M.

AGENDA

- I. Call to Order and Welcome
- II. Approval of Minutes: March 20, 2014 Meeting
- III. Old Business
  - i. Adempas<sup>®</sup>
- IV. New Business
  - a. New Products to Market
    - i. Orenitram<sup>™</sup>
    - ii. Zontivity<sup>™</sup>
    - iii. Velphoro<sup>®</sup>
    - iv. Tanzeum<sup>™</sup>
    - v. Otezla<sup>®</sup>
    - vi. Entyvio<sup>™</sup>
    - vii. Zykadia<sup>™</sup>
    - viii. Zohydro ER<sup>™</sup>
    - ix. Evzio<sup>™</sup>
    - x. Aptiom<sup>®</sup>
    - xi. Hetlioz<sup>®</sup>
    - xii. Anoro<sup>™</sup> Ellipta<sup>™</sup>
    - xiii. Sivextro<sup>™</sup>
    - xiv. Luzu<sup>®</sup>
    - xv. Jublia<sup>®</sup>
  - b. Existing Class Reviews
    - i. Topical Antifungal Agents
    - ii. Topical Antiviral Agents
    - iii. Topical Antibiotic Agents
    - iv. Topical Antiparasitic Agents
    - v. Topical Psoriasis Agents
    - vi. Oral Psoriasis Agents
    - vii. Oral Acne Agents
    - viii. Otic Antibiotics
    - ix. Otic Anti-Infective/Anesthetic/Anti-Inflammatories
    - x. Alpha Blockers for BPH
    - xi. 5-Alpha Reductase Inhibitors
    - xii. 5-Alpha Reductase Inhibitors Clinical Criteria

- xiii. Tadalafil (Cialis<sup>®</sup>) Clinical Criteria
- xiv. Bladder Relaxants
- xv. Oral Oncology Agents
- c. New Class Reviews
  - i. Vaginal Antibiotics
  - ii. Irritable Bowel Syndrome
  - iii. Irritable Bowel Syndrome Clinical Criteria
  - iv. Topical Rosacea Agents
- d. Clinical Criteria Reviews
  - i. Palivizumab (Synagis<sup>®</sup>)
  - ii. Botulinum Toxins
  - iii. Clonidine Patch
  - iv. Phenoxybenzamine (Dibenzyl<sup>®</sup>)
  - v. Lidocaine Patch (Lidoderm<sup>®</sup>)
  - vi. Capsaicin Patch (Qutenza<sup>®</sup>)
  - vii. Prenatal Vitamins
  - viii. Becaplermin (Regranex<sup>®</sup>)
  - ix. Peginterferon Alfa 2b (Sylatron<sup>™</sup>)
  - x. Omalizumab (Xolair<sup>®</sup>)
- V. Adjournment
  - a. Next Meeting
    - i. November 20, 2014
    - ii. January 15, 2015
  - b. Collection of Travel Vouchers

**PUBLIC SPEAKERS:** If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

<https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>